A review based on a quick and heavily compromised cost-effectiveness evaluation conducted in secret with a threat to delist unless the company accepted a significant price reduction. Apparently, this is what constitutes a pricing negotiation in 2019. …
Latest Video
New Stories
-
FDA rejects Sarepta's second RNA therapy
August 21, 2019 - - Latest News -
PAGE co-founders on 'opening the door' to discussions on diversity
August 21, 2019 - - Latest News -
Biogen backs new learning resource
August 21, 2019 - - Latest News -
Sigma launches pharmacy-based telehealth service
August 21, 2019 - - Latest News -
Bayer agrees to sell animal health business
August 21, 2019 - - Latest News -
PM: Look beyond 'corporate interests' on policy
August 20, 2019 - - Latest News -
Is the policy-implementation split really that simple?
August 20, 2019 - - Comment